Edition:
United States

Mallinckrodt Plc (MNK.N)

MNK.N on New York Stock Exchange

21.81USD
20 Nov 2017
Change (% chg)

$-0.57 (-2.55%)
Prev Close
$22.38
Open
$22.29
Day's High
$22.29
Day's Low
$21.15
Volume
758,468
Avg. Vol
709,024
52-wk High
$58.09
52-wk Low
$19.00

Chart for

About

Mallinckrodt public limited company develops, manufactures, markets and distributes branded and generic specialty pharmaceutical products and therapies. The Company focuses on various therapeutic areas, such as autoimmune and rare disease specialty areas, including neurology, rheumatology, nephrology, ophthalmology and... (more)

Overall

Beta: 1.50
Market Cap(Mil.): $2,072.06
Shares Outstanding(Mil.): 95.00
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 31.35 15.79
EPS (TTM): -- -- --
ROI: -- 15.11 12.01
ROE: -- 16.52 15.91

BRIEF-James Flynn reports 6.07 pct passive stake in Mallinckrodt

* James Flynn reports 6.07 percent passive stake in mallinckrodt plc ‍​as of November 7 - sec filing Source text: (http://bit.ly/2zEbVNx) Further company coverage:

Nov 13 2017

Mallinckrodt dives as sales of main drug Acthar disappoint

Shares of Mallinckrodt Plc plunged more than 30 percent to an all-time low on Tuesday after the drugmaker reported disappointing quarterly revenue and warned of slower sales of Acthar, its biggest source of revenue.

Nov 07 2017

UPDATE 1-Mallinckrodt dives as sales of main drug Acthar disappoint

Nov 7 Shares of Mallinckrodt Plc plunged more than 30 percent to an all-time low on Tuesday after the drugmaker reported disappointing quarterly revenue and warned of slower sales of Acthar, its biggest source of revenue.

Nov 07 2017

Mallinckrodt slumps as Achtar drug sales disappoint

Nov 7 Shares of Mallinckrodt Plc were down about 9 percent in premarket trading on Tuesday after the drugmaker reported lower-than-expected quarterly revenue, hurt mainly by weak sales of its Acthar drug.

Nov 07 2017

BRIEF-Mallinckrodt Q3 earnings per share $0.66

* Mallinckrodt Plc reports earnings results for third quarter of fiscal 2017

Nov 07 2017

BRIEF-Mallinckrodt to acquire Ocera Therapeutics and OCR-002, its proprietary therapy

* Mallinckrodt to acquire Ocera Therapeutics and OCR-002, its proprietary therapy in development for treatment of hepatic encephalopathy

Nov 02 2017

BRIEF-Mallinckrodt presents multiple sclerosis relapse data at Ectrims-Actrims Meet

* Mallinckrodt plc presents multiple sclerosis (ms) relapse data at 7th joint ectrims-actrims meeting (msparis2017) Source text for Eikon: Further company coverage:

Oct 26 2017

BRIEF-Mallinckrodt to conduct Phase 4 trial of H.P. Acthar Gel

* Mallinckrodt will conduct Phase 4 trial of H.P. Acthar® Gel (repository corticotropin injection) for symptomatic sarcoidosis

Oct 09 2017

BRIEF-Mallinckrodt says ‍four product launches expected over next three years​

* Mallinckrodt Plc discusses pipeline transformation, company outlook at investor briefing

Oct 04 2017

BRIEF-Mallinckrodt licenses inhaled xenon gas therapy development product

* Mallinckrodt Plc says ‍under terms of agreement, later today Mallinckrodt will pay $10 million upfront with cash on hand​

Oct 02 2017

Competitors

  Price Chg
Meda AB (MEDAa.ST) -- --
Merck KGaA (MRCG.DE) €90.74 +0.50
AB Science SA (ABS.PA) €8.91 -0.03

Earnings vs. Estimates